Wealth Alliance Has $1.22 Million Position in Novo Nordisk A/S (NYSE:NVO)

Wealth Alliance increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,836 shares of the company’s stock after acquiring an additional 313 shares during the period. Wealth Alliance’s holdings in Novo Nordisk A/S were worth $1,224,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Cornerstone Planning Group LLC acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $29,000. Tower Research Capital LLC TRC boosted its position in Novo Nordisk A/S by 165.3% in the first quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock valued at $32,000 after buying an additional 124 shares in the last quarter. Pacific Center for Financial Services boosted its position in Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Valued Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $28,000. Finally, Copeland Capital Management LLC boosted its position in Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after buying an additional 141 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.4 %

NVO opened at $123.45 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The company has a market cap of $553.99 billion, a price-to-earnings ratio of 45.64, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41. The firm has a 50 day simple moving average of $126.16 and a 200 day simple moving average of $110.32. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a dividend of $0.664 per share. This represents a dividend yield of 0.9%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s payout ratio is 49.17%.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Monday, April 1st. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target on the stock. UBS Group began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.